16 September 2026 editorial review · Item
SIG-002 (Lilly/Sigilon Afibromer-encapsulated islets): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: Lilly/Sigilon primary corporate/SEC history and SIG-001 registry were reviewed. Hemophilia-platform failure does not prove SIG-002 failure, and silence does not prove cancellation. Removed the false assertion that only one person ever carried an insulin-producing graft without immunosuppression.
- Registry NCT04541628: TERMINATED; updated 2024-09-04; enrollment 3 (ACTUAL); primary completion 2022-10-28 (ACTUAL); results posted.
- Programme/sponsor/conference source boundary: Lilly to Acquire Sigilon Therapeutics (manufacturer); Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes (manufacturer); Lilly Clinical Development Pipeline (manufacturer).